Hemang Pandya, MD
Retina Specialist · Plano, TXNPI 1700100229
Payments from drug & device makers
Across 303 payments — averaging $666.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$103K
- Boehringer Ingelheim$46K
- Astellas Pharma US Inc$18K
- Regeneron$9K
- Harrow Eye, LLC$3K
- Dutch Ophthalmic, USA$3K
- plus $20K from 27 others
Across 2 payments — averaging $52.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$105
What the payments were for
- Consulting fees$21,63714%
- Speaking & faculty fees$107,90870%
- Travel & lodging$13,3669%
- Food & beverage$10,0657%
- Education$1280%
- Entertainment$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 93 | $102,774 |
| Boehringer Ingelheim | 4 | $45,749 |
| Astellas Pharma US Inc | 22 | $17,870 |
| Regeneron | 16 | $9,344 |
| Harrow Eye, LLC | 3 | $3,176 |
| Dutch Ophthalmic, USA | 10 | $3,137 |
| Alimera Sciences, Inc. | 8 | $2,977 |
| AbbVie(2 entities) | 27 | $2,947 |
| Thrombogenics, Inc. | 5 | $2,691 |
| GSK | 1 | $2,220 |
| Boehringer Ingelheim International GmbH | 24 | $2,090 |
| Regeneron Healthcare Solutions, Inc. | 19 | $1,752 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Genentech USA, Inc. | 21 | $834 |
| Notal Vision, Inc. | 4 | $618 |
| Eyepoint US, Inc. | 7 | $407 |
| Bausch & Lomb Americas Inc. | 4 | $250 |
| Apellis Pharmaceuticals, Inc. | 5 | $239 |
| Mallinckrodt Hospital Products Inc. | 2 | $213 |
| Coherus Oncology, Inc. | 3 | $192 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $176 |
| Genentech, Inc. | 3 | $147 |
| Astellas Pharma Global Development | 2 | $111 |
| Topcon Healthcare, Inc. | 3 | $103 |
| Carl Zeiss Meditec, Inc. | 2 | $102 |
| Biotissue Holdings Inc. | 4 | $87 |
| Ivantis, Inc | 1 | $38 |
| Optos, Inc. | 2 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Heidelberg Engineering, Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$201,965 in reported general payments places this provider in the 85th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 81 | $3,532 |
| MoxifloxacinMoxifloxacin Hcl | 56 | $1,055 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $688 |
| Ketorolac Tromethamine | 29 | $361 |
| Latanoprost | 20 | $175 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Plano
- Matthew AdamsPlano$31K
- Brian BergerAustin$7.7M
- Richard LaneSan Antonio$4.7M
- Emmanuel ChangBellaire$3.7M
- Jeremiah BrownSchertz$3M
- Victor GonzalezMcAllen$2.1M
- Courtney CrawfordBurleson$1.2M
- Cecilia SanchezAustin$893K
- Sarah HolySan Antonio$689K
- Lindsey HarrisHouston$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.